MRK250103C75000
- 0.00
- 0.000.00%
Merck & Co Newsroom
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Merck to Buy Vaccine Plant From WuXi Biologics: Report
Citi's Recommended List of Large-cap Stocks: GOOGL, STZ, DAL, and More
WUXI BIO (02269.HK) is selling its Irish vaccine facility to Merck for 0.5 billion USD.
WUXI BIO (02269.HK) announced the sale of assets related to the Irish vaccine facility to Merck (MSD International), which includes properties, production equipment, contractual interests related to the Irish vaccine facility as the seller, work-in-progress inventory, and other intangible assets, with a total consideration of approximately 0.5 billion USD (approximately 3.9 billion HKD). It is expected that the asset Trade will not result in any significant gains or losses.
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
WuXi AppTec has reached an agreement with Merck regarding its vaccine factory in Ireland.
Wuxi Haide (WuXi Vaccines) is a wholly-owned subsidiary of WUXI BIO (02269), focusing on the contract customized research and development and production (CDMO) Business of vaccines.
Express News | RPT-WuXi Biologics - Wuxi Vaccines Ireland to Sell All Property and Assets Related to Vaccines Ireland Facility
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Express News | Leptraza has been approved in China for adjuvant treatment of early high-risk breast cancer with gBRCA mutations and HER2 negative.
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
New changes in the "Trump Trade".
From "re-inflation" to "tightening panic".
Brand Prescription Drugs to Rise an Average 4.5% in 2025
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
These Are the Best and Worst Stocks This Year
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Express News | UK's Mhra: Sotatercept Approved to Treat Adult Patients With Pulmonary Arterial Hypertension (Pah)
Merck & Co., Inc. (NYSE:MRK) Is a Favorite Amongst Institutional Investors Who Own 79%